Mouse IFN-γ T cell ELISPOT antibody pair - 10-plate

SKU
CT655-10
Validated ELISPOT antibody pair; reagents available separately (960 determinations).
Format
10-plate
Price
€ 655
Documentation
Data sheet
Manual
SDS
Reactivity
Mouse
Category
T cell ELISPOT
Analyte
IFN-γ
Description
Our ELISPOT antibody pairs are validated for high assay performance using the same reagents and materials included in U-CyTech ELISPOT kits. These antibody pairs are optimized for reliable and reproducible ELISPOT assays.
The antibody pairs are available in convenient 10-plate and 20-plate format, providing 960 or 1920 determinations, respectively.
Compatible reagents for ELISPOT assays can be purchased separately, allowing customization of your ELISPOT workflow.
Description
IFN-γ is a potent immune regulating cytokine that plays a central role in activating the body’s defense against infections and malignant cells. By enhancing antigen presentation and boosting the activity of T cells and natural killer (NK) cells, IFN-γ drives strong antiviral and anti tumor responses. It is primarily produced by activated T helper 1 (Th1) cells, cytotoxic T cells, γδ T cells, NK cells, and natural killer T (NKT) cells, making it a key indicator of cellular immune activation in research and diagnostic applications.
Alternative names
IFN-γ, IFN-gamma, IFN-g, IFNg, interferon γ, interferon-γ, interferon-gamma, interferon gamma, INF-g, INF-gamma, immune interferon, Type II interferon
Gene ID
15978

References

Authors, et al. Title Journal Year Volume Pages
Shanthi Herath Fusion of ubiquitin to HIV gag impairs human monocyte-derived dendritic cell maturation and reduces ability to induce gag T cell responses PLoS One 2014 9 e88327
Fang Wang Increased antigen presentation but impaired T cells priming after upregulation of interferon-beta induced by lipopolysaccharides is mediated by upregulation of B7H1 and GITRL PLoS One 2014 9 e105636
S Hu CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection J Appl Microbiol 2013 115 1203-11
Shu-Jie Liao HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo J Huazhong Univ Sci Technolog Med Sci 2013 33 735-742
Omid Chavoshian Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice Iran J Basic Med Sci 2013 16 965-72
Yingying Yan Autophagy enhances antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein Oncol Rep 2013 30 993-9
Christian Grossardt Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine Hum Gene Ther 2013 24 644-54
Xuan Wang A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice Cancer Immunol Immunother 2013 62 1261-72
Rachid Boucherma HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses J Immunol 2013 191 583-93
Ling Tao Enhanced protective efficacy of H5 subtype influenza vaccine with modification of the multibasic cleavage site of hemagglutinin in retroviral pseudotypes Virol Sin 2013 28 136-45